Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Canada Aims For 10 Biosimilar Launches In Next Decade

Pegfilgrastim And Rituximab Biosimilars Coming Soon

Executive Summary

Speaking with Generics Bulletin as Sandoz Canada unveiled its landmark public education campaign, The Biosimilars Generation, Karine Matteau, the company’s biosimilars leader, talked about how it plans to remain a leader in the biosimilars field as well as the company’s response to the COVID-19 pandemic.

You may also be interested in...



Sandoz Canada Joins Humira Biosimilar Race With Hyrimoz Approval

Sandoz Canada is looking to roll out its biosimilar to AbbVie’s Humira early in the new year following approval from Health Canada, with multiple other adalimumab candidates also reportedly approved.

Valeo Pharma To Launch Enoxaparin In Canada Early Next Year

Canadian firm Valeo Pharma is looking to make a splash with enoxaparin biosimilars, Redesca and Redesca HP, following approval from Health Canada.

Merck Matches Sandoz With Canadian Etanercept Indications

Merck, Sharp & Dohme’s Brenzys biosimilar version of Amgen’s Enbrel has received four new indications in Canada, bringing it in line with Sandoz’ rival biosimilar, Erelzi.

Related Content

Topics

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel